The United Kingdom and the United States have reached a significant bilateral deal that will keep no import taxes on British pharmaceutical shipments going into the US market.
The Terms of the Pact
As part of the deal, the UK has committed to increase funding on medicines through the National Health Service (NHS). This move secures that duties on these vital products will stay at nothing for a duration of the next three years.
This agreement is in response to recent threats to dramatically increase duties on branded pharmaceutical products, with potential rates floated as high as one hundred percent.
"This deal with the UK strengthens the global environment for new treatments and establishes long-overdue equity to transatlantic pharmaceutical trade," a release declared.
Trade Significance
Drugs are one of the the United Kingdom's most significant goods shipped to the America, which is by far the largest market for major UK drugmakers.
Statistics indicate that in the one-year period prior to last September, the UK sold drugs totaling billions to the US. This value accounted for 17.4% of total UK exports in that timeframe.
"This agreement protects work, boosts investment and facilitates the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Key British Pledges
The pact entails several key changes from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to increase overall public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum manufacturers must return to the NHS to stay within budget will be limited at 15%. Last year, rebates were more than twenty percent.
Industry Background
The deal takes place against a ongoing dispute between the drug companies and the UK government over medicine costs and NHS adoption.
This friction were exacerbated by claims that American patients were paying significantly more for the identical medicines than patients in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been delayed or abandoned, while major investments have been announced toward projects in the United States.
One official stated that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the past decade.
